Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 43 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/9/2007 First Published: 5/28/2004


1.		Phase III Randomized Study of Paclitaxel With or Without GW572016 as First-Line Therapy in Women With Advanced or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GSK-EGF30001 NCT00075270

Last Modified: 8/10/2007 First Published: 6/23/2004


2.		Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GSK-EGF100151 UCLA-0403074-01, NCT00078572


3.		Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				EGF104900 NCT00320385

Last Modified: 11/7/2007 First Published: 11/22/2004


4.		Phase I/II Study of Lapatinib in Patients With Recurrent Malignant Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				CAN-NCIC-IND170 NCIC-170, NCT00099060, IND170


5.		Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				CRC 0503 NCT00316407


6.		GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				20 to 74				Pharmaceutical / Industry				EGF105635 NCT00371488

Last Modified: 7/21/2008 First Published: 11/1/2007


7.		Phase I/II Randomized Pilot Study of Neoadjuvant Lapatinib Ditosylate in Women With Ductal Carcinoma In Situ of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Temporarily closed				21 and over				NCI				BCM-H-19895 H-19895, BCM-P50-CA-58183, NCT00555152

Last Modified: 9/28/2006 First Published: 12/21/2002


8.		Phase II Study of GW572016 in Women With Advanced or Metastatic Breast Cancer Refractory to First-Line Trastuzumab (Herceptin) and Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0208079 GSK-EGF20002, NCT00051103

Last Modified: 5/12/2004 First Published: 1/26/2003


9.		Phase II Study of GW572016 as Second-Line Therapy in Patients With Stage IV Colorectal Cancer Refractory to Irinotecan and Fluorouracil

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				GSK-EGF20004 UCLA-0209047

Last Modified: 8/8/2008 First Published: 8/24/2003


10.		Phase II Study of GW572016 in Women With Stage IIIB or IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				GSK-EGF20008 GSK-RM2002/00356/01, UCLA-0303056, NCT00062686

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute